Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Gil Stelzer works in the Department of Molecular Genetics at the Weizmann Institute of Science.
More GEN Content From This Contributor:
- Columns: Gene Trends: Which Ones Should You Be Studying Now?
- Columns: Gene Trends: Eye-Openers for Unusual Gene Variations
- GEN Exclusives: Gene Trends: On Muscle, Fat, and Brain